BAX
Baxter International Inc. NYSE Listed Oct 27, 1981$17.50
After hrs
$18.16
+0.94%
Mkt Cap $9.0B
52w Low $15.73
10.4% of range
52w High $32.68
50d MA $17.67
200d MA $20.56
P/E (TTM)
-9.8x
EV/EBITDA
23.3x
P/B
1.4x
Debt/Equity
1.6x
ROE
-15.6%
P/FCF
30.4x
RSI (14)
—
ATR (14)
—
Beta
0.62
50d MA
$17.67
200d MA
$20.56
Avg Volume
9.5M
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
One Baxter Parkway · Deerfield, IL 60015 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | 0.31 | 0.36 | +16.1% | 16.90 | +4.9% | +4.0% | +1.8% | -1.7% | -0.9% | +0.5% | — |
| Feb 12, 2026 | BMO | 0.53 | 0.44 | -17.0% | 22.28 | -12.4% | -16.0% | -11.2% | -6.9% | -1.8% | -4.2% | — |
| Oct 30, 2025 | BMO | 0.60 | 0.69 | +15.0% | 22.42 | -15.5% | -14.5% | -17.6% | -18.8% | -20.0% | -19.9% | — |
| Jul 31, 2025 | BMO | 0.60 | 0.59 | -1.7% | 28.05 | -15.3% | -22.4% | -21.7% | -20.0% | -18.6% | -19.8% | — |
| May 1, 2025 | BMO | 0.48 | 0.55 | +13.8% | 31.17 | +3.1% | -1.6% | -1.5% | -2.4% | -4.0% | -1.4% | — |
| Feb 20, 2025 | BMO | 0.53 | 0.58 | +9.8% | 30.82 | +8.0% | +8.5% | +9.7% | +13.8% | +16.6% | +14.4% | — |
| Nov 8, 2024 | BMO | 0.78 | 0.80 | +2.6% | 36.04 | -1.6% | -3.9% | -5.0% | -6.1% | -9.5% | -12.0% | — |
| Aug 6, 2024 | BMO | 0.66 | 0.68 | +2.7% | 34.64 | +1.0% | +6.6% | +5.6% | +8.0% | +7.2% | +6.6% | — |
| May 2, 2024 | BMO | 0.61 | 0.65 | +7.1% | 40.34 | -3.1% | -8.5% | -8.6% | -9.5% | -10.5% | -11.4% | — |
| Feb 8, 2024 | BMO | 0.86 | 0.88 | +2.3% | 39.38 | -1.0% | +2.7% | +0.4% | +2.4% | +0.6% | +0.7% | — |
| Nov 2, 2023 | BMO | 0.66 | 0.68 | +3.0% | 32.79 | +0.3% | +4.5% | +3.6% | +5.2% | +4.3% | +3.8% | — |
| Jul 27, 2023 | BMO | 0.59 | 0.55 | -6.8% | 48.95 | -3.5% | -7.1% | -4.0% | -7.6% | -8.1% | -10.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $16.68 | $16.66 | -0.1% | -0.2% | -0.4% | +3.4% | +3.7% | +2.8% |
| Mar 11 | Citigroup | Maintains | Neutral → Neutral | — | $17.46 | $17.51 | +0.3% | +3.4% | +3.2% | -0.3% | -2.2% | +0.9% |
| Feb 17 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.79 | $20.09 | +1.5% | +4.8% | +10.5% | +7.8% | +9.0% | +7.4% |
| Feb 13 | Barclays | Maintains | Overweight → Overweight | — | $18.71 | $18.67 | -0.2% | +5.8% | +10.8% | +16.9% | +14.1% | +15.3% |
| Jan 9 | Barclays | Maintains | Overweight → Overweight | — | $20.69 | $20.90 | +1.0% | +1.8% | -2.6% | -5.0% | -4.1% | -1.5% |
| Dec 2 | Morgan Stanley | Maintains | Underweight → Underweight | — | $19.08 | $18.99 | -0.5% | -1.3% | -1.0% | -3.1% | -2.8% | -4.8% |
| Oct 31 | Citigroup | Maintains | Neutral → Neutral | — | $19.16 | $18.81 | -1.8% | -3.6% | -5.0% | -6.4% | -6.3% | -6.2% |
| Oct 31 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.16 | $18.81 | -1.8% | -3.6% | -5.0% | -6.4% | -6.3% | -6.2% |
| Oct 31 | Argus | Downgrade | Buy → Hold | — | $19.16 | $18.81 | -1.8% | -3.6% | -5.0% | -6.4% | -6.3% | -6.2% |
| Oct 31 | UBS | Maintains | Neutral → Neutral | — | $19.16 | $18.81 | -1.8% | -3.6% | -5.0% | -6.4% | -6.3% | -6.2% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $23.15 | $23.27 | +0.5% | -1.1% | -1.7% | -2.8% | -5.2% | -4.5% |
| Aug 4 | Barclays | Maintains | Overweight → Overweight | — | $21.96 | $21.83 | -0.6% | +2.2% | +4.0% | +2.5% | +7.2% | +7.9% |
| Aug 4 | Stifel | Downgrade | Buy → Hold | — | $21.96 | $21.83 | -0.6% | +2.2% | +4.0% | +2.5% | +7.2% | +7.9% |
| Aug 4 | UBS | Maintains | Neutral → Neutral | — | $21.96 | $21.83 | -0.6% | +2.2% | +4.0% | +2.5% | +7.2% | +7.9% |
| Aug 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $21.76 | $21.51 | -1.1% | +0.9% | +3.1% | +5.0% | +3.4% | +8.2% |
| Jul 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $28.53 | $28.71 | +0.6% | -1.0% | -0.6% | -2.2% | -2.7% | -4.1% |
| Jul 9 | Citigroup | Maintains | Neutral → Neutral | — | $30.66 | $30.96 | +1.0% | -2.8% | -3.1% | -6.4% | -6.9% | -7.9% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $29.69 | $29.69 | +0.0% | +3.3% | +0.4% | +0.0% | -3.3% | -3.9% |
| May 5 | Morgan Stanley | Maintains | Underweight → Underweight | — | $30.71 | $30.32 | -1.3% | -0.9% | -2.5% | +0.0% | +1.6% | +0.6% |
| May 2 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $30.67 | $31.06 | +1.3% | +0.1% | -0.8% | -2.4% | +0.2% | +1.7% |
| Mar 10 | Barclays | Maintains | Overweight → Overweight | — | $36.57 | $36.69 | +0.3% | -0.0% | -2.0% | -5.9% | -5.5% | -5.4% |
| Feb 21 | JP Morgan | Maintains | Neutral → Neutral | — | $33.44 | $33.51 | +0.2% | +1.1% | +4.9% | +7.5% | +5.4% | +5.0% |
| Dec 11 | Citigroup | Maintains | Neutral → Neutral | — | $31.44 | $31.48 | +0.1% | -1.4% | -1.9% | -3.6% | -6.4% | -5.7% |
| Nov 11 | Stifel | Maintains | Buy → Buy | — | $34.64 | $35.00 | +1.0% | -1.2% | -2.3% | -5.8% | -8.5% | -7.7% |
| Oct 1 | Citigroup | Maintains | Neutral → Neutral | — | $37.97 | $38.01 | +0.1% | -2.8% | -5.3% | -7.6% | -4.3% | -5.8% |
| Aug 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $36.59 | $36.68 | +0.2% | +2.3% | +1.5% | +0.9% | -5.7% | -2.9% |
| Aug 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $36.92 | $37.52 | +1.6% | -0.9% | +1.4% | +0.6% | +0.0% | -6.5% |
| Aug 7 | JP Morgan | Maintains | Neutral → Neutral | — | $36.92 | $37.52 | +1.6% | -0.9% | +1.4% | +0.6% | +0.0% | -6.5% |
| Jul 15 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $35.32 | $34.20 | -3.2% | -3.8% | +0.6% | +1.0% | +1.0% | +0.1% |
| Jul 10 | Citigroup | Maintains | Neutral → Neutral | — | $34.01 | $33.90 | -0.3% | +0.7% | +3.6% | +3.9% | -0.1% | +4.5% |
| Jul 2 | Evercore ISI | Maintains | Outperform → Outperform | — | $33.06 | $33.10 | +0.1% | -0.6% | +0.3% | +5.6% | +1.7% | +2.9% |
| May 22 | Citigroup | Maintains | Neutral → Neutral | — | $34.45 | $34.38 | -0.2% | -0.3% | -1.3% | -1.6% | -1.7% | -3.7% |
| May 10 | TD Cowen | Downgrade | Buy → Hold | — | $35.95 | $35.62 | -0.9% | -0.7% | -1.4% | -2.0% | -1.4% | -2.2% |
| Apr 3 | Citigroup | Maintains | Neutral → Neutral | — | $42.91 | $42.96 | +0.1% | +0.9% | -0.7% | -0.7% | -1.5% | -0.2% |
| Mar 5 | BofA Securities | Maintains | Neutral → Neutral | — | $42.50 | $43.56 | +2.5% | -0.2% | +1.2% | +2.3% | +3.0% | +2.3% |
| Feb 12 | Barclays | Maintains | Overweight → Overweight | — | $39.55 | $39.69 | +0.4% | +1.9% | +0.2% | +0.2% | +3.5% | +4.2% |
| Feb 9 | JP Morgan | Maintains | Neutral → Neutral | — | $40.46 | $40.50 | +0.1% | -2.2% | -0.4% | -2.1% | -2.0% | +1.2% |
| Dec 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $36.55 | $36.27 | -0.8% | +0.9% | -2.1% | -1.7% | -0.1% | -1.1% |
| Oct 31 | JP Morgan | Maintains | Neutral → Neutral | — | $32.04 | $32.07 | +0.1% | +1.2% | +2.3% | +6.9% | +6.0% | +7.6% |
| Aug 21 | Citigroup | Maintains | Neutral → Neutral | — | $41.79 | $42.06 | +0.6% | +0.6% | -0.4% | -0.9% | -0.8% | -0.6% |
| Aug 1 | Barclays | Maintains | Overweight → Overweight | — | $45.23 | $45.30 | +0.2% | -0.5% | -2.9% | -2.9% | -2.9% | -3.7% |
| Jul 31 | Barclays | Maintains | Overweight → Overweight | — | $47.01 | $46.95 | -0.1% | -3.8% | -4.3% | -6.6% | -6.5% | -6.6% |
| Jul 31 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $47.01 | $46.95 | -0.1% | -3.8% | -4.3% | -6.6% | -6.5% | -6.6% |
| Jul 28 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $45.48 | $45.57 | +0.2% | +3.4% | -0.5% | -1.1% | -3.5% | -3.4% |
| Jul 12 | Stifel | Maintains | Buy → Buy | — | $46.03 | $46.47 | +1.0% | +0.8% | +1.5% | +1.8% | +1.1% | +2.2% |
| May 1 | Barclays | Maintains | Overweight → Overweight | — | $47.68 | $47.59 | -0.2% | -0.6% | -1.4% | -2.5% | -5.0% | -3.4% |
| Apr 28 | Deutsche Bank | Maintains | Hold → Hold | — | $46.80 | $46.94 | +0.3% | +1.9% | +1.2% | +0.4% | -0.6% | -3.2% |
| Apr 28 | Citigroup | Maintains | Neutral → Neutral | — | $46.80 | $46.94 | +0.3% | +1.9% | +1.2% | +0.4% | -0.6% | -3.2% |
| Apr 28 | Stifel | Maintains | Buy → Buy | — | $46.80 | $46.94 | +0.3% | +1.9% | +1.2% | +0.4% | -0.6% | -3.2% |
| Apr 28 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $46.80 | $46.94 | +0.3% | +1.9% | +1.2% | +0.4% | -0.6% | -3.2% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Vafa Jamali's appointment as director signals potential strategic shifts in governance and decision-making, warranting investor attention to board composition changes affecting corporate direction and oversight quality.
Apr 6
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A new executive at Baxter or Inogen with a $525,000 base salary and 70% bonus potential signals leadership continuity, but investors should monitor whether this hire strengthens operational execution or represents reactive replacement.
Mar 30
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Baxter is communicating adjusted financial metrics to shareholders, signaling management's focus on operational performance rather than reported results, which typically indicates confidence in underlying business strength despite potential accounting headwinds.
Mar 19
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Baxter International made a material announcement on March 16, 2026, requiring SEC disclosure, likely signaling executive or strategic news that could impact investor expectations and stock valuation.
Mar 16
8-K · 5.02
!!! Very High
Baxter International Inc. -- 8-K 5.02: Executive Change
Baxter International appointed Michael R. McDonnell as Executive Vice President effective February 13, 2026, signaling internal leadership development and potential changes to executive responsibilities.
Feb 12
Data updated apr 24, 2026 8:36pm
· Source: massive.com